Research graph
References from Germ line landscape stratification defines distinct molecular and prognostic groups in therapy-related myeloid neoplasms. Local targets link to admitted publications; unresolved targets remain external evidence.
Molecular International Prognostic Scoring System for myelodysplastic syndromes
10.1056/evidoa2200008 · 2022 · External reference
The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms
10.1038/s41375-022-01613-1 · 2022 · External reference
International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data
10.1182/blood.2022015850 · 2022 · External reference
Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications
10.3324/haematol.2022.281233 · 2022 · External reference
Therapy-related myeloid neoplasm: biology and mechanistic aspects of malignant progression
10.3390/biomedicines12051054 · 2024 · External reference
Post-cytotoxic myeloid neoplasms: a comprehensive analysis of clinicopathologic, genetic profile, latency determinants, and potential prognostic predictors- a single centre study
10.1007/s00277-025-06651-0 · 2025 · External reference
Unanswered questions following reports of secondary malignancies after CAR-T cell therapy
10.1038/s41591-023-02767-w · 2024 · External reference
Therapy-related myeloid neoplasms: when genetics and environment collide
10.1038/nrc.2017.60 · 2017 · External reference
Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study
10.1200/jco.2014.60.0890 · 2015 · External reference
Therapy-related myeloid neoplasms: complex interactions among cytotoxic therapies, genetic factors, and aberrant microenvironment
10.1158/2643-3230.bcd-24-0103 · 2024 · External reference
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS
10.1038/s41375-020-0917-7 · 2021 · External reference
The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution
10.1038/s41375-019-0479-8 · 2019 · External reference
TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype
10.1182/blood.2022018236 · 2023 · External reference
Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome
10.1182/blood.2021014472 · 2022 · External reference
Therapy-related myelodysplastic syndromes in the genomics era
10.1016/j.bulcan.2023.02.022 · 2023 · External reference
PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy
10.1016/j.stem.2018.10.004 · 2018 · External reference
Genomics of therapy-related myeloid neoplasms
10.3324/haematol.2019.219352 · 2020 · External reference
Family history of breast or ovarian cancer modifies the risk of secondary leukemia after breast cancer: results from a population-based study
10.1002/ijc.23212 · 2008 · External reference
Lenalidomide promotes the development of TP53 -mutated therapy-related myeloid neoplasms
10.1182/blood.2021014956 · 2022 · External reference
The secondary myelodysplastic neoplasms (MDS) jigsaw
10.3390/cancers15051483 · 2023 · External reference
Confirming putative variants at ≤ 5% allele frequency using allele enrichment and Sanger sequencing
10.1038/s41598-021-91142-1 · 2021 · External reference
Association of chemotherapy for solid tumors with development of therapy-related myelodysplastic syndrome or acute myeloid leukemia in the modern era
10.1001/jamaoncol.2018.5625 · 2019 · External reference
Revised International Prognostic Scoring System for myelodysplastic syndromes
10.1182/blood-2012-03-420489 · 2012 · External reference
Cancer therapy shapes the fitness landscape of clonal hematopoiesis
10.1038/s41588-020-00710-0 · 2020 · External reference
Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma
2008 · External reference
Comparison of survival benefits of combined chemotherapy and radiotherapy versus chemotherapy alone for uterine serous carcinoma
10.1097/igc.0000000000000856 · 2017 · External reference
Chemotherapy alone versus definitive concurrent chemoradiotherapy for cT4b esophageal squamous cell carcinoma: a population-based study
10.1186/s12876-021-01742-4 · 2021 · External reference
Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials
10.1200/jco.2012.44.5791 · 2013 · External reference
Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia
10.1038/nature13968 · 2015 · External reference
Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation
10.1056/nejmoa1611604 · 2017 · External reference
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
10.1038/s41591-020-1008-z · 2020 · External reference
TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML
10.1182/bloodadvances.2021006239 · 2022 · External reference
Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study
10.1016/s1470-2045(16)30626-x · 2017 · External reference
Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia
10.1002/cncr.29615 · 2016 · External reference
Germline predisposition in myeloid neoplasms: unique genetic and clinical features of GATA2 deficiency and SAMD9/SAMD9L syndromes
10.1016/j.beha.2020.101197 · 2020 · External reference
Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia
10.1182/blood-2015-04-641100 · 2015 · External reference
Molecular pathogenesis in myeloid neoplasms with germline predisposition
2021 · External reference
Universal genetic testing for inherited susceptibility in children and adults with myelodysplastic syndrome and acute myeloid leukemia: are we there yet?
10.1038/s41375-018-0051-y · 2018 · External reference
Germline predisposition to hematopoietic malignancies
10.1093/hmg/ddab141 · 2021 · External reference
Beyond myeloid neoplasms germline guidelines: validation of the thresholds criteria in the search of germline predisposition variants
10.1002/jha2.1012 · 2024 · External reference
BCHE as a prognostic biomarker in endometrial cancer and its correlation with immunity
2022 · External reference
Mono-allelic MUTYH mutation as the likely inherited etiology of hereditary breast cancer in a patient from a multi-cancer family- report of a family and literature review
10.1186/s12920-025-02213-5 · 2025 · External reference
Regulator of telomere elongation helicase 1 gene and its association with malignancy
2023 · External reference
Age of first cancer diagnosis and survival in Bloom syndrome
10.1016/j.gim.2022.03.008 · 2022 · External reference
